Few data are available regarding the evolution of Crohn's disease after discontinuing a successful course of infliximab.
Dr Domènech and colleagues from Spain evaluated clinical outcome of Crohn's disease.
The researchers evaluated outcomes after induction of remission with 3 infliximab infusions.
The research team also assessed the outcomes after maintenance of remission with 1-year course of infliximab every 8 weeks.
The team included 23 patients with active luminal Crohn's disease who responded to 3 infusions of infliximab at 0, 2, and 6 weeks.
|After infliximab discontinuation, only 34% maintained remission at 1 year|
|Alimentary Pharmacology & Therapeutics|
A further 23 patients with sustained response to infliximab every 8 weeks during 1 year were included.
The researchers followed up the patients until relapse or for at least 6 months after infliximab discontinuation.
The researchers evaluated clinical outcomes and factors associated to relapse.
In luminal Crohn's disease, a 3-infusion infliximab regimen achieved a sustained response in most patients, especially with complete response at the time of the third infusion.
In patients treated for 1-year, infliximab discontinuation was also successful, with a cumulative probability of being free of relapse of 69% at 12 months.
The team noted that in perianal disease, early relapse was the rule after stopping infliximab treatment, with only 34% of patient maintaining remission at 1 year.
Dr Domènech's team concluded, “Short regimens of infliximab might be evaluated in patients with luminal Crohn's disease.”
“However, infliximab discontinuation is not recommended in perianal Crohn's disease, because of a high rate of early relapse.”